Estee Lauder Companies Inc vs Globus Medical Inc. Class A Common Stock — how do they compare? Estee Lauder Companies Inc trades at $101.76 (market cap $36.13B), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: Estee Lauder Companies Inc is far larger — about 3.5× Globus Medical Inc. Class A Common Stock's market cap, and Estee Lauder Companies Inc pays a 1.4% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Estee Lauder Companies Inc for 123 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| EL | GMED | |
|---|---|---|
Market Cap | $36.13B | $10.25B |
Volume | 1,925,948 | 1,108,124 |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $96.82 |
52-Week Low | $67.23 | $58.33 |
Typical Hold Time | 123 Days | 0 Days |
Enterprise Value | $41.88B | $9.76B |
Dividend Yield | 1.4% | — |
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $101.59, up 1.55% with strong technical momentum and bullish moving average signals. The company shows improving operational trends with three consecutive quarterly earnings beats, though 2025 results reflect a net loss of $1.13B amid revenue contraction. Recent strategic partnerships in AI marketing and leadership appointments signal transformation efforts, while analyst consensus remains positive with a $103 price target.
The stock presents a turnaround opportunity with margin recovery potential and digital innovation initiatives, but faces execution risks from competitive pressures and debt levels. Current valuation multiples appear elevated relative to profitability metrics, requiring careful monitoring of Q3 2026 earnings delivery for confirmation of sustained improvement.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →